Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained
Stock Performance: Wild Swings from Deaths to Resumption SRPT has been a roller-coaster. In early 2025, Sarepta’s shares were largely pummeled by the DMD gene-therapy crisis. After two Duchenne patients (non-ambulatory teens)